SPRO — Spero Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1701108 ·
Last close
$2.10
Market Cap
$121.59M
52W High
$3.08
52W Low
$1.95
ADV30
1,417,904
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 258,000 | — | -7,538,000 | -7,203,000 | 59,021,000 | 56,129,000 | 6,087,000 |
| Dec 2025 | 39,658,000 | — | 31,405,000 | 31,520,000 | 68,919,000 | 40,265,000 | 9,898,000 |
| Sep 2025 | 3,048,000 | — | -7,329,000 | -7,382,000 | 54,170,000 | 48,616,000 | 27,676,000 |
| Jun 2025 | 11,802,000 | — | -2,361,000 | -1,700,000 | 62,119,000 | 31,194,000 | 29,291,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$7,242,000
Investing CF
—
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.24
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-458,269,000
Inventory
—
Receivables
$44,000
ST Investments
—
EBIT TTM
$14,177,000
Pretax Income TTM
$15,496,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$61,186,000
EBITDA
—
Free Cash Flow
$13,249,625
Enterprise Value
$69,096,168
Total Cash
$56,129,000
Total Debt
$2,474,000
Shares Out
57,901,493
Trailing EPS
$0.27
Book Value
$0.91
ROE
35.1%
ROA
13.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 59,619,000 | 7,159,000 | 8,572,000 | 68,919,000 | 9,898,000 | — | -12,624,000 |
| Dec 2024 | 27,396,000 | -72,484,000 | -68,566,000 | 110,543,000 | 64,420,000 | — | -23,444,000 |
| Dec 2023 | 96,735,000 | 26,787,000 | 22,806,000 | 182,390,000 | 75,496,000 | — | -32,995,000 |
| Dec 2022 | 48,579,000 | -30,567,000 | -46,415,000 | 124,802,000 | 48,868,000 | — | -7,731,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.11
Max Pain — expiry 2026-07-17
max pain strike: $2.50 · spot: $2.10 · call oi: 8,817 · put oi: 1,262
Expected Move to 2026-07-17:
±$0.45
(21.43%) —
implied range
$1.65 –
$2.55
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COYA | Coya Therapeutics, Inc. | $123.38M | $5.26 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $124.86M | $2.07 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $116.43M | $4.49 | — |
| BGM | BGM Group Ltd. | $127.51M | $0.34 | — |
| PMN | ProMIS Neurosciences Inc. | $127.79M | $14.25 | — |
News headlines (Yahoo Finance, 1h cache)
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
2026-07-08 06:00 · Yahoo
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
2026-06-29 11:30 · Yahoo
GSK (LSE:GSK) Wins FDA Approval For Utebzi As Momelotinib Gains Orphan Tag
2026-06-26 14:07 · Yahoo
Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?
2026-06-24 13:27 · Yahoo
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
2026-06-21 14:31 · Yahoo
Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)
2026-06-18 13:52 · Yahoo
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
2026-06-17 20:21 · Yahoo
Promising Penny Stocks To Consider In May 2026
2026-05-15 12:05 · Yahoo
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
2026-05-13 20:05 · Yahoo
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
2026-04-22 22:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.